Drug Profile
Research programme: radionuclide oncology therapeutics - ITM Group
Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator itm Group
- Developer ITM Group
- Class Radioisotopes; Radiopharmaceuticals
- Mechanism of Action DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone metastases; Neuroendocrine tumours; Prostate cancer; Skin cancer
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for clinical-Phase-Unknown development in Bone metastases in Germany (Parenteral)
- 28 Apr 2019 No recent reports of development identified for clinical-Phase-Unknown development in Neuroendocrine-tumours in Germany (Parenteral)
- 28 Apr 2019 No recent reports of development identified for clinical-Phase-Unknown development in Prostate-cancer in Germany (Parenteral)